#Japan #Tokyo #RNA Therapeutics #patent strategy #nucleic acid medicines

Future of Nucleic Acid Medicines: A Seminar Overview

In light of the rapid developments in nucleic acid medicines, a seminar titled "Redefining the Landscape of Nucleic Acid Medicines: Entry Strategies for the 2030s" is scheduled for July 16, 2026, from 10:00 AM to 4:30 PM via Zoom. This seminar, organized by the IR Technology Education Institute, aims to provide attendees with comprehensive insights into the landscape of RNA therapeutics, including patent trends and strategies for entering the market.

Nucleic acid medicines, which include RNA therapeutics, are emerging as a new modality following small molecules and antibody drugs. The approval of Spinraza (ASO) in 2017 and Onpattro (siRNA) in 2019 has signalled a significant shift in the market, leading to increased product launches in Japan. However, the journey is fraught with challenges, such as complex intellectual property structures, technical hurdles, and the critical technologies that drive practical applications. The upcoming decade, specifically the 2030s, is particularly crucial as many existing patents will begin to expire, creating both opportunities and uncertainties.

Seminar Curriculum

This one-day seminar is designed to equip participants with practical knowledge tailored to the unique landscape of nucleic acid medicines, addressing critical topics such as:

• - Basics of RNA Therapies: An overview of siRNA and ASO, their mechanisms of action, and product characteristics.
• - Manufacturing and Quality Control (CMC): Understanding synthesis, purification, analysis, quality control, Good Manufacturing Practice (GMP), technology transfer, and contract development manufacturing organizations (CDMOs).
• - Patent Structures: A look at the four-layer model of nucleic acid medicines' patent structures.
• - Historical Patent Trends for siRNA and ASO: An analysis of foundational patents, modification motifs, launch products, and the impact of patent expiries.
• - DDS Patent Competition: Evaluation of leading technologies like GalNAc and LNP, comparing different companies' approaches.
• - Patent Landscape: Insights into the top ten companies and the fifteen key target genes in the nucleic acid sector.
• - Patent Disputes and Licensing Strategies: Transition into topics surrounding cross-licensing, litigation frameworks, and freedom to operate.
• - Understanding the Patent Cliff: Key timelines for the expiry of major patents affecting drug releases.
• - Industry Structure and Strategy: Insights into the value chain of RNA medicines, the position of Japanese companies, and strategic pathways such as proprietary technology, licensing except post-expiry followers.

Target Audience

This seminar is particularly beneficial for:

• - Pharmaceutical and Biotech Professionals: Individuals involved in R&D, intellectual property, and business development.
• - Technical Staff from CDMOs: Those considering entry into the nucleic acid medicines market.
• - Investors and Consultants: Professionals analyzing the RNA therapeutics landscape.
• - Researchers and Collaborators: Academics and public research entities aiming for practical application.

No prior deep knowledge of nucleic acids, RNA, or patent law is required, just a basic understanding of pharmaceutical development processes.

For participants interested in expanding their knowledge and acquiring practical strategies for success in the nucleic acid therapeutics arena, this seminar is a not-to-be-missed opportunity.

For more details and registration, please visit IR Technology Education Institute.

With ongoing commitment to delivering essential knowledge and skills to the manufacturing industry through seminars, e-learning, and training, the IR Technology Education Institute continues to empower professionals for a successful future.

For inquiries about our services, reach out to Japan IR, renowned for over 50 years in the patent and intellectual property solutions field, as well as other technical services including research and education targeted at professionals in the industry. Visit our official website for further insights.